Pfizer Limited Stock Price Today (NSE: PFIZER)
Fundamental Score
Pfizer Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Pfizer Limited share price today is ₹4014.40, down 0.67% on NSE/BSE as of 16 September 2026. Pfizer Limited (PFIZER) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹18.37K (Cr). The 52-week high for PFIZER share price is ₹5578.50 and the 52-week low is ₹3955.50. At a P/E ratio of 24.98x, PFIZER is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 17.16% and a debt-to-equity ratio of 0.00.
Pfizer Limited Share Price Chart — NSE/BSE Historical Performance
Pfizer Limited share price chart: -11.62% return over the past month. 52-week high ₹5578.50, 52-week low ₹3955.50.
Pfizer Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹4052.00 | ₹4080.00 | ₹3955.50 | ₹4014.40 | 37.28K (Cr) | |
| ₹4075.00 | ₹4091.10 | ₹4026.20 | ₹4041.60 | 36.14K (Cr) | |
| ₹4103.10 | ₹4123.80 | ₹4054.00 | ₹4060.20 | 1.39L (Cr) | |
| ₹4175.80 | ₹4195.10 | ₹4080.00 | ₹4095.40 | 2.67L (Cr) | |
| ₹4310.70 | ₹4318.00 | ₹4158.40 | ₹4171.00 | 1.26L (Cr) | |
| ₹4530.00 | ₹4580.80 | ₹4300.00 | ₹4310.70 | 1.87L (Cr) | |
| ₹4598.80 | ₹4610.00 | ₹4557.00 | ₹4596.50 | 17.55K (Cr) | |
| ₹4628.20 | ₹4667.90 | ₹4575.00 | ₹4609.70 | 32.74K (Cr) | |
| ₹4680.00 | ₹4695.00 | ₹4601.00 | ₹4643.70 | 10.61K (Cr) | |
| ₹4625.30 | ₹4655.90 | ₹4614.00 | ₹4627.60 | 9.43K (Cr) |
Pfizer Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹4684.40 | ₹4707.80 | ₹3955.50 | ₹4014.40 | -14.30% | |
| ₹4823.90 | ₹5149.00 | ₹4673.00 | ₹4684.40 | -2.89% | |
| ₹4449.90 | ₹4848.10 | ₹4426.00 | ₹4823.90 | +8.40% | |
| ₹4580.00 | ₹4708.10 | ₹4360.10 | ₹4439.40 | -3.07% | |
| ₹4701.10 | ₹5035.40 | ₹4521.00 | ₹4598.50 | -2.18% | |
| ₹4746.10 | ₹5045.00 | ₹4648.00 | ₹4710.60 | -0.75% | |
| ₹4912.00 | ₹5008.00 | ₹4522.00 | ₹4720.50 | -3.90% | |
| ₹4550.00 | ₹5257.00 | ₹4460.00 | ₹5062.20 | +11.26% | |
| ₹4940.00 | ₹5002.20 | ₹4541.00 | ₹4563.60 | -7.62% | |
| ₹4976.00 | ₹5166.30 | ₹4855.20 | ₹4987.70 | +0.24% | |
| ₹5212.50 | ₹5339.00 | ₹4948.00 | ₹4975.00 | -4.56% | |
| ₹5200.00 | ₹5578.50 | ₹5101.00 | ₹5209.00 | +0.17% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Pfizer Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Pfizer Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PFIZER across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (17.16%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (22.81%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (35.85%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 24.98 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Conservative Debt Levels (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (103.92x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 6.17)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹2754.32 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (63.92%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Growth History (2.39% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Pfizer Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Pfizer Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Pfizer LimitedPfizer Limited...Selected✓ PFIZER • 500680 | 52.1/100 | ₹4014.40₹4014 | ₹18365.88₹18365.88 | 24.98Average 25.0 Average | 17.16%Good 17.16% Good | 22.81%Excellent 22.81% Excellent | 0.00Excellent 0.0 Excellent | 7.74%Good 7.74% Good | 2.39%Average 2.39% Average | 1.59% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Pfizer Limited PE Ratio History
Historical price-to-earnings ratio for PFIZER — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹167.79 | ₹4987.70 | 29.7x |
| FY 2024 | ₹120.51 | ₹5281.50 | 43.8x |
| FY 2023 | ₹136.38 | ₹4268.95 | 31.3x |
| FY 2022 | ₹133.89 | ₹4431.70 | 33.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Pfizer Limited Dividend History
Annual cash dividends paid by PFIZER — dividend yield 1.59%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹160.25 Cr |
| FY 2024 | ₹183.43 Cr |
| FY 2023 | ₹297.21 Cr |
| FY 2022 | ₹159.74 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Pfizer Limited Quarterly Performance
Latest quarterly metrics for PFIZER — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
8.31%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
6.63%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
2.39%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
7.74%
Compounded annual net profit growth over 5 years
Pfizer Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PFIZER — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Pfizer Limited Financial Statements
Annual income statement, balance sheet and cash flow for Pfizer Limited (PFIZER) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Pfizer Limited
About PFIZER (Pfizer Limited)
Pfizer Ltd is a significant player in the pharmaceutical sector, dedicated to the development, production, and global distribution of a diverse range of medical solutions. The comp...any's operations encompass the entire pharmaceutical value chain, from pioneering research and cutting-edge manufacturing to strategic marketing and widespread product availability. Pfizer Ltd demonstrates a strong commitment to addressing critical healthcare needs across numerous therapeutic areas, ensuring access to essential medications for patients worldwide. Through robust supply chains and collaborative partnerships, Pfizer Ltd strives to deliver impactful healthcare solutions, contributing to improved patient outcomes and overall public health. The corporation maintains stringent quality control standards throughout its processes, guaranteeing the safety and efficacy of its products and upholding its reputation as a trusted provider of pharmaceutical interventions. Pfizer Ltd distinguishes itself through its comprehensive portfolio of pharmaceutical products, targeting a wide spectrum of medical conditions and patient demographics. The company's offerings span critical therapeutic categories, including treatments for neurological disorders, cardiovascular diseases, oncological ailments, and infectious diseases. Pfizer Ltd maintains a strong presence in specialized areas such as hormone therapies, pain management, and urological health. Furthermore, the company recognizes the importance of preventative care, offering a range of vaccines and nutritional supplements to promote overall well-being. By catering to diverse medical needs, Pfizer Ltd aims to provide integrated healthcare solutions that improve the quality of life for individuals across different age groups and health conditions. This broad approach reflects the company's commitment to addressing the evolving healthcare challenges of modern society. Pfizer Ltd actively engages with healthcare professionals and institutions to foster collaboration and ensure the responsible use of its pharmaceutical products. The company is dedicated to providing comprehensive information and resources to support informed decision-making in patient care. Pfizer Ltd invests in ongoing research and development to discover and deliver innovative treatments for unmet medical needs. The company also actively participates in public health initiatives, working alongside governments and organizations to improve access to healthcare and promote disease prevention. With a strong focus on ethical practices and scientific rigor, Pfizer Ltd strives to uphold its commitment to improving global health and making a positive impact on the lives of patients worldwide.
Company Details
Key Leadership
PFIZER Share Price: Frequently Asked Questions
What is the current share price of Pfizer Limited?
Pfizer Limited (PFIZER) trades at ₹4014.40 on NSE and BSE. Market cap ₹18.37K (Cr). Educational data only.
What is the P/E ratio of Pfizer Limited?
Pfizer Limited has a P/E of 24.98x vs industry average 34.89x.
What is the Bull Run score for Pfizer Limited?
Pfizer Limited has a Bull Run score of 52.1/100 based on 25+ financial parameters.
Does Pfizer Limited pay dividends?
Pfizer Limited has a dividend yield of 1.59%. Past dividends don't guarantee future payments.
What is the ROE of Pfizer Limited?
Pfizer Limited has ROE of 17.16%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Pfizer Limited?
Pfizer Limited has debt-to-equity of 0.00.
Is Pfizer Limited a good investment?
Bull Run gives Pfizer Limited a score of 52.1/100. This is not investment advice — consult a SEBI-registered advisor.